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Abstract 
This paper empirically examines the influence of firms’ one-year lagged of total new 
products (t-1), one-year lagged profitability (t-1), and market share of new products to 
firms’ amount of sales revenue in pharmaceutical generic companies in Indonesia. The data 
used in this study was panel dataset, gathered from six large pharmaceutical generic 
companies in Indonesia, during the period 2006 to 2010. The regression analysis method 
uses fixed effect models, with generalized least squares (GLS) method. The result shows 
that firms’ one-year lagged of total new product (t-1), one-year lagged profitability (t-1), 
and market share of new products to be positive and affect significantly the firms’ sales 
revenue in the pharmaceutical generic companies in Indonesia. 
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1. Introduction 
To protect new innovations in the pharmaceutical market, the patent is used to restrict 
competing firms from copying the innovation within a certain period. Generics are known 
as certified drugs equivalent to those brand-name medicines that are allowed to enter the 
market when the patents of original drugs expire (Moreno-Torres, Puig-Junoy, and Borrell-
Arque, 2007). In Indonesia, generic drugs might be a key driver of competition and cost 
containment in pharmaceutical markets, because almost all pharmaceutical companies in 
Indonesia, produce generic drugs. In Indonesia, generics are authorized when twenty years 
have passed since the original brand-name drug was introduced in the market. Because of 
many pharmaceutical companies producing generic drugs, the price competition between 
generic competitors is stronger in Indonesia. Based on Moreno-Torres, Puig-Junoy, and 
Borrell-Arque (2007) a study was conducted in Spain, concluding that there are four driver 
keys for fostering generic entry, that being: 1) when the number of generic firms already in 
the market increases, there are more direct competitors and the average number of generic 
entries turn lower; 2) number of active ingredients per therapeutic subgroup that decreases 
the average number of generic entries; 3) market size in terms of revenues, which affects 
positively; and 4) the time trend has significant fostering effect on generic entry. 
Several studies were focused on generic entry in pharmaceutical industries. Rudholm 
(2001), found that expected profits affected positively the number of generic entries, but the 
longer the exclusivity period of the brand-name product, the lower the likelihood of generic 
entry. However, Reiffen and Ward (2005) empirically suggested that the larger expected 
profits could be expected to occur with more and faster entry into the generic markets.  
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Profitability of the drug industry is an important issue because profits provide a way for 
pharmaceutical firms to gauge what types of product consumers value most (A 
Congressional Budget Office Study, 2006). Chen, Chang, and Lin (2006) empirical studies, 
found that larger firms must increase their profitability, in order to invest more in R&D 
resources, and then increase their innovation performance. In pharmaceutical business, 
profits are important stimuli and become a source of funding for research and development 
activity, which in turn leads to a stream of health-enhancing new products (F.M. Scherer, 
2001). We have shown previously that one-year lagged profitability has a positive and 
significant effect on firms’ amount of R&D expenditure in multinational R&D based 
pharmaceutical companies (Simanjuntak and Tjandrawinata, 2011). As time goes by, an 
increase in the number of new products that they produce will increase their sales revenue. 
More consumers use the new products, the more markets share of these products, and 
ultimately it will affect their sales revenue.  
The main purpose of this study is to show the effect of profitability, total new products 
and market share of new product on firms’ amount of sales revenue on pharmaceutical 
generic companies. In this paper, we expect to observe our hypothesis, that is:  
Hypothesis 1: Firms’ amount of profitability is positively associated with firms’ amount of 
sales revenue. 
Hypothesis 2: Firms’ amount of total new products is positively associated with firms’ 
amount of sales revenue. 
Hypothesis 3: Market share of new products is positively associated with firms amount of 
sales revenue.  
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Following hypothesis formulation, a model was devised to investigate the relation of 
each hypothesis on the model of total sales in the generic pharmaceutical company. We 
found that firms’ one-year lagged of total new product (t-1), one-year lagged profitability 
(t-1), and market share of new product have been positive and affect significantly the firms’ 
sales revenue in the pharmaceutical generic companies in Indonesia. 
 
2. Data and Methodology 
2.1 Samples and Data Collection 
This research was conducted in the generic firms of the pharmaceutical industry in 
Indonesia. Financial data used in this study, were obtained from annual financial reports of 
each pharmaceutical company as well as the IMS (Intercontinental Marketing Services) 
database. This study analyzed six Indonesia public pharmaceutical generic companies 
(which are owned by domestic companies), Kalbe, Tempo Scan Pacific, Kimia Farma, 
Indofarma, Pyridam, and Darya Varia as samples in this study. Data used in this study were 
taken from the period 2006 to 2010. Since there are one-year lags in the profitability (t-1) 
and total new product (t-1) variable, then the whole panel data observations become 24 
observations. The definitions and measurements of these constructs were further defined as 
follows: 
1. Sales Revenue 
Total sales revenue was used as the dependent variable in our model. Total sales 
revenue data was obtained from the income statement contained in the annual financial 
statement of each pharmaceutical company.  
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2. Profitability 
One-year lagged (t-1) profit after tax was used as the proxy data for profitability. The 
data was obtained from the income statement contained in the published annual 
financial statements of the pharmaceutical companies.  
3. New Product 
The data used as a new product variable was obtained from total new generic products 
produced by each generic pharmaceutical company every year. This data was obtained 
from IMS (Intercontinental Marketing Services) database. New products are defined as 
those products launched within the past 24 months.  
4. Market Share 
The data used as a proxy for market share of generic new products was obtained from 
IMS (Intercontinental Marketing Services) database. 
 
2.2 Methodology and Models  
This study was conducted by using regression analysis method using fixed effect 
model, with generalized least squares (GLS) method. In the fixed effect model, it is 
assumed that although the intercept may differ across individuals, each individual’s 
intercept does not vary over time; it is time invariant (Gujarati, 2003). Each cross-sectional 
unit has its own (fixed) intercept value, in all N (observations) such values for N cross-
sectional units in fixed effect model (Gujarati, 2003). GLS was necessary to correct for 
within-group and contemporaneous serial correlation (Vernon, Golec, Lutter, and 
Nardinelli, 2006). The purpose of this study is to examine that there is a positive 
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relationship between the firms’ one-year lagged of total new product (t-1), one-year lagged 
profitability (t-1), and market share of a new product to the firms’ amount of sales revenue 
in pharmaceutical companies, especially in pharmaceutical generic companies, during the 
period 2006 until 2010. The model equations used in this study is: 
      (1) 
Logarithmic transformation is used for all variables contained in the model, except for 
market share, because with logarithmic value, elasticity value is obtained, making it easier 
for us to see clearly and interpret the relationship between the dependent and independent 
variables. Market share variable was represented as percentages value, and as such it does 
not need to be represented in logarithmic scale. In the model described above, the 
coefficient of each independent variable (slope) shows the elasticity of the firms’ one-year 
lagged of total new product, one-year lagged probability, and market share to the firms’ 
sales revenue, respectively. This shows the percentage change in the firms’ sales revenue, 
for one percentage change in the firms’ one-year lagged of total new product (t-1), one-year 
lagged profitability (t-1), and market share.  
 
3. Result 
As seen in Table 1 (based on Model 1), a positive and statistically significant 
relationship existed between log(NP?(-1)) and log(SALES?). The positive relationship 
between firms’ one-year lagged of total new product and firms’ sales means enhancement 
in firms’ one-year lagged of total new product can increase their current sales revenue. Our 
elasticity estimates showed 0.25 percent, which means that a one percent increase 
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(decrease) in firms’ one-year lagged of total new product will be accompanied by 0.25 
percent increase (decrease) in firms’ amount of sales revenue. This is caused when the total 
companies’ new product increased, the value of sales revenue in the future would also 
indirectly increase. The Congressional Budget Office Study (2006) noted that successful 
new drugs will generate large cash flow that can be invested in R&D, and in turn will 
increase their innovation and also their sales revenue. This supports the hypothesis that the 
firms’ amount of total new products is positively associated with the firms’ amount of sales 
revenue.  
A positive and statistically significant relationship between log(PROFIT?(-1)) and 
log(SALES?) has also been seen in our calculation (Table 1). This positive relationship 
between firms’ one-year lagged profitability and sales means that enhancement in firms’ 
one-year lagged profitability can increase their current sales revenue. Our elasticity 
estimates suggested that a one percent increase (decrease) in firms’ one-year lagged 
profitability will be accompanied by 0.28 percent increase (decrease) in firms’ amount of 
sales revenue. Chen, Chang, and Lin (2006) proposed that pharmaceutical companies 
should raise their profitability, so that they can invest more in the R&D resources to 
increase their innovation performance. When their innovation increased, more new 
products will be produced, and subsequently they will contribute to the increased sales 
revenue. This supports the hypothesis that the firms’ profitability is positively correlated 
with the firms’ total sales revenue. 
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Table 1: Model (1) Result of Regression Analysis Based on a Panel of Six 
Pharmaceutical Generic Companies in Indonesia, Period 2006 – 2010 
Dependent Variable: LOG(SALES?) 
Total pool (balanced) observations: 24 
Variable Coefficient Std. Error t-Statistic Prob.   
C 14.91777 0.858092 17.38483*** 0 
LOG(NP?(-1)) 0.259354 0.054599 4.750194*** 0.0003 
LOG(PROFIT?(-1)) 0.282415 0.057548 4.907437*** 0.0002 
MS? 0.181022 0.076884 2.354463** 0.0326 
R-squared 0.953576       
Adjusted R-squared 0.928816       
F-statistic 38.5132       
Durbin-Watson stat 1.804561       
      Two-tail significance levels: 
* Significant at level 10 % 
** Significant at level 5 % 
*** Significant at level 1 % 
 
  With regard to the market shares of total new products, a result depicted on Table 1 
was seen following analysis based on Model 1. The results indicated a positive and 
statistically significant relationship between MS? and log(SALES?). The positive 
relationship between market share and sales means that enhancement in market share of 
total new products at present can increase their current sales revenue. Our elasticity 
estimate shows to be 0.18 percent, suggesting that one percent increase (decrease) in 
current market share of total new products will be accompanied by 0.18 percent increase 
(decrease) in firms’ amount of sales revenue. When the market share of new products 
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increases, many consumers are expected to use the products, therefore increase in sales 
revenues, is seen to occur. 
 
4. Conclusion 
The purpose of this study was to examine the influence of total profitability, total new 
products, and market share of new products on the firms’ amount of sales revenue on 
pharmaceutical generic companies in Indonesia. Regression analysis has shown a positive 
and statistically significant influence, thus, enhancement in the firms’ one-year lagged of 
total new generic product, one-year lagged of total profitability, and market share of total 
new product can increase firms’ amount of sales revenue on pharmaceutical generic 
companies. Thus it can be concluded that sales revenue on pharmaceutical generic 
companies in Indonesia, strongly influenced by their profitability, the total new generic 
product that they produce, and market share of their new generic products.  
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